KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Current Assets (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Current Assets for 7 consecutive years, with $438.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets changed 0.39% year-over-year to $438.7 million, compared with a TTM value of $438.7 million through Sep 2025, changed 0.39%, and an annual FY2024 reading of $446.6 million, up 5.13% over the prior year.
  • Current Assets was $438.7 million for Q3 2025 at Aurinia Pharmaceuticals, up from $409.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $513.3 million in Q4 2021 and bottomed at $329.2 million in Q3 2021.
  • Average Current Assets over 5 years is $424.2 million, with a median of $424.8 million recorded in 2023.
  • Peak annual rise in Current Assets hit 39.63% in 2022, while the deepest fall reached 13.79% in 2022.
  • Year by year, Current Assets stood at $513.3 million in 2021, then decreased by 13.79% to $442.5 million in 2022, then decreased by 4.01% to $424.8 million in 2023, then grew by 5.13% to $446.6 million in 2024, then decreased by 1.76% to $438.7 million in 2025.
  • Business Quant data shows Current Assets for AUPH at $438.7 million in Q3 2025, $409.0 million in Q2 2025, and $405.8 million in Q1 2025.